Structure-Based Virtual Screening of the Nociceptin Receptor: Hybrid Docking and Shape-Based Approaches for Improved Hit Identification
暂无分享,去创建一个
Pankaj R. Daga | Willma E. Polgar | Nurulain T. Zaveri | P. Daga | N. Zaveri | W. Polgar | Pankaj R. Daga
[1] Woody Sherman,et al. Use of an Induced Fit Receptor Structure in Virtual Screening , 2006, Chemical biology & drug design.
[2] Mark A. Weston,et al. Synthesis and evaluation of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one analogues as NOP receptor agonists with analgesic and sedative properties. , 2007, Bioorganic & medicinal chemistry.
[3] F. Monsma,et al. Moving from the Orphanin FQ Receptor to an Opioid Receptor Using Four Point Mutations* , 1996, The Journal of Biological Chemistry.
[4] G. Adam,et al. Synthesis of (1S,3aS)-8-(2,3,3a,4,5, 6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4. 5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties. , 2000, European journal of medicinal chemistry.
[5] G. V. van Westen,et al. GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A2B receptor , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[6] Santiago Vilar,et al. Application of Monte Carlo-based receptor ensemble docking to virtual screening for GPCR ligands. , 2013, Methods in enzymology.
[7] J. Meunier,et al. Different domains of the ORL1 and κ‐opioid receptors are involved in recognition of nociceptin and dynorphin A , 1998, FEBS letters.
[8] N. Zaveri,et al. Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): Ligand-based analysis of structural factors influencing intrinsic activity at NOP , 2005, The AAPS Journal.
[9] Claudio N. Cavasotto,et al. Representing receptor flexibility in ligand docking through relevant normal modes. , 2005, Journal of the American Chemical Society.
[10] A. Rodomonte,et al. Synthesis and pharmacological evaluation of 1,2-dihydrospiro[isoquinoline-4(3H),4'-piperidin]-3-ones as nociceptin receptor agonists. , 2008, Journal of medicinal chemistry.
[11] Giuditta Bastanzio,et al. Development of nociceptin receptor (NOP) agonists and antagonists , 2011, Medicinal research reviews.
[12] N. Carruthers,et al. High-Affinity, Non-Peptide Agonists for the ORL 1 (Orphanin FO/Nociceptin) Receptor , 2002 .
[13] W. Greenlee,et al. Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. , 2007, Bioorganic & medicinal chemistry letters.
[14] D. Tulshian,et al. Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands: part 2. , 2009, Bioorganic & medicinal chemistry letters.
[15] D. Tulshian,et al. Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands. , 2007, Bioorganic & medicinal chemistry letters.
[16] G Vassart,et al. ORL1, a novel member of the opioid receptor family , 1994, FEBS letters.
[17] Lei Shi,et al. The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[18] F. Monsma,et al. Creating a functional opioid alkaloid binding site in the orphanin FQ receptor through site-directed mutagenesis. , 1998, Molecular pharmacology.
[19] Claudio N. Cavasotto,et al. Ligand and Decoy Sets for Docking to G Protein-Coupled Receptors , 2012, J. Chem. Inf. Model..
[20] Walter A. Korfmacher,et al. The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. , 2009, Bioorganic & medicinal chemistry letters.
[21] Ajay N. Jain. Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search , 2007, J. Comput. Aided Mol. Des..
[22] James Andrew McCammon,et al. Predictive Power of Molecular Dynamics Receptor Structures in Virtual Screening , 2011, J. Chem. Inf. Model..
[23] Jonathan A. Javitch,et al. Discovery of a Novel Selective Kappa-Opioid Receptor Agonist Using Crystal Structure-Based Virtual Screening , 2013, J. Chem. Inf. Model..
[24] R. Nussinov,et al. The role of dynamic conformational ensembles in biomolecular recognition. , 2009, Nature chemical biology.
[25] I. Peretto,et al. Lead generation and lead optimisation approaches in the discovery of selective, non-peptide ORL-1 receptor agonists and antagonists , 2001 .
[26] William L. Jorgensen,et al. Journal of Chemical Information and Modeling , 2005, J. Chem. Inf. Model..
[27] Holger Gohlke,et al. Target flexibility: an emerging consideration in drug discovery and design. , 2008, Journal of medicinal chemistry.
[28] Yanli Wang,et al. Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review , 2012, The AAPS Journal.
[29] G. Wishart,et al. Structure-activity relationships and CoMFA of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one analogues as NOP receptor agonists with analgesic properties. , 2008, Bioorganic & medicinal chemistry.
[30] H. Pajouhesh,et al. Medicinal chemical properties of successful central nervous system drugs , 2005, NeuroRX.
[31] J. Deschamps,et al. A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor. , 2004, Journal of medicinal chemistry.
[32] G. Bignan,et al. Recent advances towards the discovery of ORL-1 receptor agonists and antagonists , 2005 .
[33] T. Vanderah,et al. Recently patented and promising ORL-1 ligands: where have we been and where are we going? , 2010, Expert opinion on therapeutic patents.
[34] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[35] J. Meunier,et al. Distinct mechanisms for activation of the opioid receptor-like 1 and kappa-opioid receptors by nociceptin and dynorphin A. , 1999, Molecular pharmacology.
[36] Woody Sherman,et al. Generation of Receptor Structural Ensembles for Virtual Screening Using Binding Site Shape Analysis and Clustering , 2012, Chemical biology & drug design.
[37] Ruben Abagyan,et al. Consistent Improvement of Cross-Docking Results Using Binding Site Ensembles Generated with Elastic Network Normal Modes , 2009, J. Chem. Inf. Model..
[38] M. Mortrud,et al. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a μ, δ or κ opioid receptor type , 1994 .
[39] G. Adam,et al. Synthesis of (1S,3aS)-8- (2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro [4.5]decan-4-one, a Potent and Selective Orphanin FQ (OFQ) Receptor Agonist with Anxiolytic-Like Properties. , 2000 .
[40] Ryan G. Coleman,et al. ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..
[41] C. Kozak,et al. Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family , 1994, FEBS letters.
[42] Bryan L. Roth,et al. Structure of the Nociceptin/Orphanin FQ Receptor in Complex with a Peptide Mimetic , 2012, Nature.
[43] F. Monsma,et al. High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor. , 2000, Journal of medicinal chemistry.
[44] J. Irwin,et al. Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.
[45] G. Bignan,et al. 3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor. , 2006, Bioorganic & medicinal chemistry letters.
[46] N. Zaveri. Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. , 2003, Life sciences.
[47] J. Lewis,et al. Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors. , 2001, European journal of pharmacology.
[48] W. Greenlee,et al. Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. , 2007, Bioorganic & medicinal chemistry letters.
[49] G. Adam,et al. ORL1 receptor ligands: structure-activity relationships of 8-cycloalkyl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-ones. , 2000, Bioorganic & medicinal chemistry letters.
[50] M. Mortrud,et al. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. , 1994, FEBS letters.
[51] D. Koshland. Application of a Theory of Enzyme Specificity to Protein Synthesis. , 1958, Proceedings of the National Academy of Sciences of the United States of America.
[52] C. Topham,et al. Functional inactivation of the nociceptin receptor by alanine substitution of glutamine 286 at the C terminus of transmembrane segment VI: evidence from a site-directed mutagenesis study of the ORL1 receptor transmembrane-binding domain. , 2000, Molecular pharmacology.
[53] Pankaj R Daga,et al. Homology modeling and molecular dynamics simulations of the active state of the nociceptin receptor reveal new insights intoagonist binding and activation , 2012, Proteins.